Answers are grounded in this paper and cite their sources.
Tecarfarin, a novel vitamin K antagonist metabolized by carboxylesterase 2 rather than the CYP450 system, may offer a more stable anticoagulation alternative to warfarin in patients with severe chronic kidney disease, though further clinical trials are needed.
Vitamin K antagonists are used for the prevention of arterial and venous thrombosis since more than 60 years and were the most widely prescribed anticoagulants in the world.[1] Despite their unexcelled efficacy, the narrow therapeutic window is associated with many challenges in clinical practice.
No takes yet. Share an insight, caveat, or question.
Hobl et al. (2017) conducted an editorial in Chronic kidney disease requiring anticoagulation. Tecarfarin vs. Warfarin was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: